secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001213900-25-022947
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q4 revenue up 14% to $32.3M; FY2025 guidance at least $100M revenue
------------------------------------------------------------------------------

- Q4 revenue $32.3M (+14% YoY); gross profit $22.0M (+23% YoY, margin 68%).
- GAAP net loss $(0.1)M in Q4; full-year GAAP net loss $(20.1)M or $(1.10)/share.
- Non-GAAP net income $5.5M ($0.30 diluted) in Q4; Adj. EBITDA $8.8M (+53% YoY).
- FY2025 guidance: revenue at least $100M, adjusted EBITDA at least $12M.
- Net revenue retention 121% in 2024 vs 105% in 2023; 48 DAAP deals (up from 24).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390025022947/0001213900-25-022947-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390025022947/ea0234059-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-022947

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer